Atossa Therapeutics, Inc.

Clinical trials sponsored by Atossa Therapeutics, Inc., explained in plain language.

Atossa Therapeutics, Inc. ATOS NASDAQ

Clinical-stage biopharmaceutical company developing therapies for breast cancer and other conditions.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill combo shows promise in halting Hormone-Fueled breast tumors Results expected Nov 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1 Completed 1

Could a daily pill lower breast cancer risk by reducing breast density?

Disease control Completed

This study tested an oral drug called (Z)-endoxifen in 240 premenopausal women with high breast density, a known risk factor for breast cancer. Over six months, researchers measured changes in breast density using mammogram software. The goal was to see if the drug could safely r…

Phase 2 • Sponsor: Atossa Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:36 UTC

Atossa Therapeutics, Inc.

Upcoming readouts

Could a daily pill lower breast cancer risk by reducing breast density?